Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model
Authors:
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Behavioural Brain Research
- Vol. 365, 133-140
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (NRF-2016R1C1B2007691)
- Medical Research Center (MRC) Program
- Korea government (MSIP) (NRF-2015R1A5A2009656)
This publication has 44 references indexed in Scilit:
- A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strainsGenome Biology, 2013
- Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorderNordic Journal of Psychiatry, 2011
- Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulationBiochemical and Biophysical Research Communications, 2011
- Lessons from a Mouse Model Characterizing Features of Vascular Cognitive Impairment with White Matter ChangesJournal of Aging Research, 2011
- Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemiaJournal of Neuroscience Research, 2010
- Behavioral and psychological symptoms associated with dementia subtype and severityInternational Psychogeriatrics, 2009
- Vascular Cognitive Impairment: Small Vessels, Big TollStroke, 2009
- Intensity of chronic cerebral hypoperfusion determines white/gray matter injury and cognitive/motor dysfunction in miceJournal of Neuroscience Research, 2008
- Dysfunctional and Compensatory Prefrontal Cortical Systems, Genes and the Pathogenesis of SchizophreniaCerebral Cortex, 2007
- Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's DiseaseJournal of Clinical Psychopharmacology, 2005